文献速递颈动脉与弓上血管

颈动脉内膜切除术后旨在减少主要不良心血管事件的长期药物治疗

Long-Term Drug Therapy Following Carotid Endarterectomy Aimed at Reducing Major Adverse Cardiovascular Events.
PubMed 文献 · Ann Vasc Surg · 2024-05-28

该研究调查了347例颈动脉内膜切除术后平均108个月(范围43-185个月)患者的初级保健电子记录,比较存活者187例晚期复查时与手术时的处方,以及160例死亡者末次处方。结果显示晚期复查时抗血小板药处方比例低于手术时(143例76% vs 170例91%,P<0.01),但完全抗凝比例更高(37例 vs 4例,P<0.01),抗高血压药处方显著增加(166例89% vs 67例35%,P<0.01),总体主要不良心血管事件减少药物处方率高于预期。

要点

  • 颈动脉内膜切除术后多年主要不良心血管事件减少药物处方率高于预期。
  • 晚期复查时抗血小板药处方比例低于手术时(143例76% vs 170例91%,P<0.01)。
  • 晚期复查时抗高血压药处方显著高于手术时(166例89% vs 67例35%,P<0.01)。

核心结论

  • 颈动脉内膜切除术后多年主要不良心血管事件减少药物的处方率高于预期,部分可能归因于英国的国家医疗服务体系。

研究设计与样本

  • 检索347例颈动脉内膜切除术后平均108个月(范围43-185个月)患者的初级保健电子记录,比较存活者187例晚期复查时与手术时的处方,以及160例死亡者末次处方。

主要发现

  • 晚期复查时存活者中抗血小板药处方143例(76%)低于手术时170例(91%),P<0.01。
  • 晚期复查时完全抗凝37例高于手术时4例,P<0.01。
  • 抗血栓药总体处方率无变化(167例89% vs 172例92%)。
  • 调脂药处方晚期复查173例(93%)与手术时169例(90%)均良好。
  • 抗高血压药处方晚期复查166例(89%)显著高于手术时67例(35%),P<0.01;糖尿病治疗例数相似(64例34% vs 42例23%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Timely carotid endarterectomy (CEA) reduces the risk of future stroke. This benefit is maximized with lifelong drug therapy aimed at reducing further major adverse cardiovascular events (MACEs), including stroke. Studies suggest that around half discontinue these drugs within 12 months. To assess if this is the case following CEA, we considered the MACE-reducing drugs prescribed several years later and compared this with the drugs they were prescribed at CEA. METHODS: The electronic primary care records of 347 post-CEA patients a mean of 108 (range 43-185) months after surgery were interrogated. The prescriptions of generic MACE-reducing drugs (antithrombotic, lipid-lowering, antihypertension and diabetes) of the 187 alive were compared with their prescriptions at CEA and with the last prescription of the 160 who had died before the late review. The post-CEA incidence of further MACE in survivors was determined. RESULTS: At late review, fewer of the post-CEA patients alive were taking antiplatelet drugs (143, 76% vs. 170, 91% P < 0.01), but more were fully anticoagulated (37v4 P < 0.01) when compared with prescriptions at CEA. Overall, there was no change in antithrombotic drug prescription rates (167, 89% vs. 172, 92%). Lipid-regulating drugs were well prescribed both at late review and at CEA (173, 93% vs. 169, 90%). The number prescribed antihypertension drugs was significantly higher at late review than at CEA (166, 89% vs. 67, 35% P < 0.01). The number treated for diabetes was similar (64, 34% vs. 42, 23%). There was no difference in the numbers of any of the MACE-reducing drugs prescribed between those who had survived to late review and those who had not. At late review, of those alive, there were 22 (12%) new strokes, and 24 (14%) had developed new or worsening ischemic cardiac symptoms. CONCLUSIONS: We found a higher than expected prescription rate of MACE-reducing drugs many years after CEA. This finding may be due, in part, to the nationalized health service in the United Kingdom.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Baker D, Chen X, Rahm L, et al. Long-Term Drug Therapy Following Carotid Endarterectomy Aimed at Reducing Major Adverse Cardiovascular Events. Ann Vasc Surg. 2024. PMID: 38815904. doi:10.1016/j.avsg.2024.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。